Terms: = Thyroid cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Diagnosis
36 results:
1. Intrathyroid thymic carcinoma: A clinicopathological analysis of 22 cases.
Gao Y; Pan Y; Luo Y; Cheng R; Zhai Q
Ann Diagn Pathol; 2023 Dec; 67():152221. PubMed ID: 37925863
[TBL] [Abstract] [Full Text] [Related]
2. [Pulmonary lymphoepithelioma-like carcinoma with expression of Epstein-Barr virus and pd-l1].
Avilés-Salas A; Vélez-Valle A; Bryon-Gallego A; Arrieta O
Medicina (B Aires); 2023; 83(2):319-323. PubMed ID: 37094205
[TBL] [Abstract] [Full Text] [Related]
3. pd-l1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
[TBL] [Abstract] [Full Text] [Related]
4. [Duodenal bleeding due to metastasis from lung adenocarcinoma controlled by radiotherapy: A case report and literature review].
Severin S; Terrones Munoz V; Meert N; Peche R
Rev Mal Respir; 2023 Apr; 40(4):359-365. PubMed ID: 36868976
[TBL] [Abstract] [Full Text] [Related]
5. A case report of anterior mediastinal signet ring cell carcinoma.
Liu S; Zhao A; Mao M
Medicine (Baltimore); 2022 Dec; 101(48):e32202. PubMed ID: 36482538
[TBL] [Abstract] [Full Text] [Related]
6. Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy.
Jungels C; Pita JM; Costante G
Curr Opin Oncol; 2023 Jan; 35(1):1-9. PubMed ID: 36398690
[TBL] [Abstract] [Full Text] [Related]
7. A case of osteoclastic variant of anaplastic thyroid carcinoma: Diagnostic and prognostic marker studies by cytology.
Bantumilli S; Zhu LC; Sakthivel M; Dodd L
Diagn Cytopathol; 2022 Dec; 50(12):E357-E360. PubMed ID: 35929756
[TBL] [Abstract] [Full Text] [Related]
8. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract] [Full Text] [Related]
9. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract] [Full Text] [Related]
10. Spatially resolved immune microenvironmental profiling for follicular thyroid carcinoma with minimal capsular invasion.
Saburi S; Tsujikawa T; Miyagawa-Hayashino A; Mitsuda J; Yoshimura K; Kimura A; Morimoto H; Ohmura G; Arai A; Ogi H; Konishi E; Itoh K; Sugino K; Hirano S
Mod Pathol; 2022 Jun; 35(6):721-727. PubMed ID: 34952946
[TBL] [Abstract] [Full Text] [Related]
11. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.
Zhu C; Dai Y; Zhang H; Ruan Y; Zhou Y; Dai Y; Fan L; Jia T; Lu H; Chen Q
Diagn Pathol; 2021 Aug; 16(1):84. PubMed ID: 34465342
[TBL] [Abstract] [Full Text] [Related]
12. Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report.
Zheng L; Li L; He Q; Wang M; Ma Y; Zhu J; Li Y; Fu X; Zhang Y
Medicine (Baltimore); 2021 Aug; 100(32):e26138. PubMed ID: 34397868
[TBL] [Abstract] [Full Text] [Related]
13. Peripheral Versus Intraparenchymal Papillary thyroid Microcarcinoma: Different Morphologies and pd-l1 Expression.
Kovacevic B; Vucevic D; Cerovic S; Eloy C
Head Neck Pathol; 2022 Mar; 16(1):200-212. PubMed ID: 34076845
[TBL] [Abstract] [Full Text] [Related]
14. Metastasis of Sarcomatoid Malignant Mesothelioma With
Chen KB; Huang YJ; Huang Y; Wu ZW; Jin XL; Zhang H; Xiang XP; Chen L; Chen L
Int J Surg Pathol; 2021 Dec; 29(8):856-863. PubMed ID: 33729861
[TBL] [Abstract] [Full Text] [Related]
15. Do Molecular Profiles of Primary
Gomes-Lima CJ; Shobab L; Wu D; Ylli D; Bikas A; McCoy M; Feldman R; Lee W; Rao SN; Jensen K; Vasko V; Castro LC; Jonklaas J; Wartofsky L; Burman KD
Front Endocrinol (Lausanne); 2021; 12():623182. PubMed ID: 33716974
[TBL] [Abstract] [Full Text] [Related]
16. From biomarkers to therapeutic targets: the promise of pd-l1 in thyroid autoimmunity and cancer.
D'Andréa G; Lassalle S; Guevara N; Mograbi B; Hofman P
Theranostics; 2021; 11(3):1310-1325. PubMed ID: 33391536
[TBL] [Abstract] [Full Text] [Related]
17. [Endocrine side effects of cancer immunotherapy].
Kroiß M; Schilling B; Deutschbein T
Dtsch Med Wochenschr; 2020 Dec; 145(24):1736-1741. PubMed ID: 33254246
[TBL] [Abstract] [Full Text] [Related]
18. Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high pd-l1 and STK11: A case report.
Fricke J; Mambetsariev I; Pharaon R; Subbiah S; Rajurkar S; Salgia R
Medicine (Baltimore); 2020 Nov; 99(46):e22323. PubMed ID: 33181636
[TBL] [Abstract] [Full Text] [Related]
19. Feasibility study of cryobiopsy for practical pathological diagnosis of primary lung cancer including immunohistochemical assessment.
Nishida T; Matsumoto Y; Sasada S; Tanaka M; Nakai T; Fukai R; Ohe Y; Watanabe SI; Motoi N
Jpn J Clin Oncol; 2021 Feb; 51(2):271-278. PubMed ID: 32964232
[TBL] [Abstract] [Full Text] [Related]
20. Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre.
Gonzalez-Mazón I; Sánchez-Bilbao L; Martín-Varillas JL; García-Castaño A; Delgado-Ruiz M; Bernat Piña I; Hernández JL; Castañeda S; Llorca J; González-Gay MA; Blanco R
Clin Exp Rheumatol; 2021; 39(3):612-620. PubMed ID: 32896258
[TBL] [Abstract] [Full Text] [Related]
[Next]
